SEC Comment Letter for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105) (NMAD) — Jan 8, 2009

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105)
Date: Jan. 8, 2009 · CIK: 0001335105 · Accession: 0000000000-09-001073

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-51476

Date

January 8, 2009

Author

Tabatha Akins

Form

UPLOAD

Company

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 January 8, 2009 Dr. John S. Kovach Lixte Biotechnology Holdings, Inc. Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) 248 Route 25A, No. 2 East Setauket, New York 11733 Re: Lixte Biotechnology Holdings, Inc. Item 4.01 Form 8-K File No. 000-51476

Dear Dr. Kovach:

We have completed our review of your Form 8-K and have no further comments at this time.

S i n c e r e l y , T a b a t h a A k i n s S t a f f A c c o u n t a n t

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010           January 8, 2009  Dr. John S. Kovach Lixte Biotechnology Holdings, Inc. Chief Executive Officer and Chief Financial Officer  (Principal Executive Officer and Principal Financial Officer)
248 Route 25A, No. 2 East Setauket, New York 11733
Re: Lixte Biotechnology Holdings, Inc.
 Item 4.01 Form 8-K    File No. 000-51476

Dear Dr. Kovach:

We have completed our review of your Form 8-K and have no further comments
at this time.

       S i n c e r e l y ,            T a b a t h a  A k i n s         S t a f f  A c c o u n t a n t

SecProbe.io